FitchettDHTherouxPBrophyJM, et al. Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment; part 1: non-ST-segment elevation ACS. Can J Cardiol. 2011;27(6):S387-401.
TanguayJ-FBellADAckmanML, et al. Focused 2012 update of the Canadian Cardiovascular Society Guidelines for the use of antiplatelet therapy. Can J Cardiol. 2013;29(11):1334-45.
5.
PatelMRCalhoonJHDehmerGJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 appropriate use criteria for coronary revascularization in patients with acute coronary syndromes. J Am Coll Cardiol. 2017;69(5):570.
6.
LevineGNBatesERBittlJA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol. 2016;68(10):1082.
7.
MehtaSRBaineyKRCantorWJ, et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol. 2018;34(3):214-33.
8.
BonacaMPBhattDLCohenM, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800.
9.
EikelboomJWConnollySJBoschJ, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-30.
10.
SumayaWGeislerTKristensenSDStoreyRF.Dual antiplatelet or dual antithrombotic therapy for secondary prevention in high-risk patients with stable coronary artery disease?Thromb Haemost. 2019;119(10):1583-9.
11.
KhanS.Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607). In: KausiRFeistT, editors. London: National Institute for Health and Care Excellence; 2019.
12.
MauriLKereiakesDJYehRW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-66.
13.
BonacaMPBhattDLStegPG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016;37(14):1133-42.
14.
CoppensMWeitz JeffreyIEikelboom JohnWA.Synergy of dual pathway inhibition in chronic cardiovascular disease. Circ Res. 2019;124(3):416-25.
15.
EikelboomJWConnollySJBoschJ, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease supplementary appendix. N Engl J Med. 2017;377(14):1319-30.
16.
AnandSSBoschJEikelboomJW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219-29.
17.
BonacaMPBhattDLOude OphuisT, et al. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 trial. JAMA Cardiol. 2016;1(4):425-32.
18.
MehranRRaoSVBhattDL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736-47.
